Evaluating quality of life in prostate cancer patients after radiotherapy
Health-Related Quality of Life in Prostate Cancer Patients Treated With Radiotherapy
Erasmus Medical Center · NCT05645237
This study is trying to see how different types of radiotherapy affect the quality of life for men with localized prostate cancer before, during, and up to five years after their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Sex | Male |
| Sponsor | Erasmus Medical Center (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Rotterdam, Zuid-Holland) |
| Trial ID | NCT05645237 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess health-related quality of life (HRQL) in prostate cancer patients treated with various modern hypofractionated radiotherapy schedules. Approximately 600 patients with localized prostate cancer will participate, providing informed consent and completing validated online questionnaires before, during, and up to five years after treatment. The study will evaluate changes in HRQL levels over time, focusing on different radiotherapy modalities used at the Erasmus MC. The findings will help understand the impact of current radiotherapy practices on patient well-being.
Who should consider this trial
Good fit: Ideal candidates are men diagnosed with clinically localized prostate cancer (T1c-T4) who are referred for radiotherapy.
Not a fit: Patients who have previously received radiation treatment in the pelvic region or have other active tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into how different radiotherapy treatments affect the quality of life for prostate cancer patients.
How similar studies have performed: Other studies have successfully evaluated health-related quality of life in cancer patients, suggesting that this approach is both relevant and valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically T1c-T4, N0 (or N+ in case of EBRT-LN+), M0 prostate cancer patient referred for radiotherapy. * Willing and capable to fill out Dutch questionnaires on health-related items at a computer (online questionnaires). * Signed written Informed Consent. Exclusion Criteria: * Previously radiation treatment in the pelvic region, for any reason. * Diagnosed with other tumor in the past 12 months or known with tumor progression of another tumor. * Postoperative radiotherapy with dose levels \< 72 Gy.
Where this trial is running
Rotterdam, Zuid-Holland
- Radiotherapy, Erasmus MC Cancer Center — Rotterdam, Zuid-Holland, Netherlands (RECRUITING)
Study contacts
- Principal investigator: Luca Incrocci, MD PhD — Erasmus Medical Center
- Study coordinator: Wilma Heemsbergen, PhD
- Email: w.heemsbergen@erasmusmc.nl
- Phone: +31650033202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, prostate cancer, radiotherapy, hypofractionation, health-related quality of life